[ad_1] The Food and Drug Administration just approved its most expensive drug ever — a hemophilia B gene therapy from Carlisle Companies (CSL) and UniQure (QURE) — and QURE stock popped Wednesday. X Meanwhile, BioMarin (BMRN) shares broke out after the FDA said it wouldn’t hold an advisory committee meeting to discuss its hemophilia A